The latest news, announcements and press releases from Viralgen.
Viralgen has been serving the rapidly expanding gene therapy market with its robust AAV manufacturing platform since 2018, supporting customers in preclinical through phase 2. Viralgen’s new facility, located in the same technology park as Viralgen’s existing manufacturing footprint, expands capacity more than 5-fold and enables full support of customer projects from early pre-clinical through to commercial scale. Equipment validation and facility certification activities will continue throughout 2021 with the first commercial-grade 2,000L batches released by mid-2022. This expansion has been designed in compliance with the most advanced sustainability standards regarding energy use, waste management, and water consumption It represents more than €70M investment for its first phase and will reach €120M when the next two buildings are completed. The new commercial facility will bring 130 additional highly qualified new jobs to Viralgen which should represent a team of over 250 people in 2022.
This is the News section of the company profile page for Viralgen on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.